The market size of the Global Immunology Drugs Market in the year 2021 is valued at 88.85 billion and is predicted to reach 183.49 billion by the year 2030 at an 8.7% CAGR during the projected period.
The medical and biological research field known as Immunology Drugs focuses on the immune system. Autoimmune disorders develop when the immune system assaults the body that it is supposed to defend. People with autoimmune disorders have a deficiency in their immune system that prevents them from telling "self" molecules apart from "non-self" or "foreign" molecules. Numerous laboratory tests are available in Immunology Drugs to identify autoimmune disorders. The increased frequency of immunological illnesses brought on by environmental changes and changing lifestyles, as well as the increased awareness of immunological disease in both developed and developing nations, are the driving forces behind the market's expansion. Some of the major market participants are continually emphasizing innovation and expanding their product lines to improve patient treatment outcomes. It is anticipated that this will expand even further during the projection period. There is a growing patient population with autoimmune illnesses as a result of many environmental variables such as stress, infection, exposure to hazardous chemicals, and nutritional components.
The worldwide Immunology Drugs industry is likely to experience growth restraints over the forecast period due to a lack of technological advancements and expensive treatment costs. Additionally, many negative effects are associated with these treatments, such as fever, irregular or pounding heartbeat, muscle aches, allergic reactions, infections, etc. Therefore, the aforementioned limitations and the stringent reimbursement practices in emerging countries hinder market expansion throughout the projection period.
The Immunology Drugs Market is segmented on the basis of Drug Class, Distribution Channel, and Disease Indications. Based on Drug Class, the market is segmented into Monoclonal antibodies, Fusion Proteins, Immunosuppressants, Polyclonal antibodies, and Other Drug classes. Based on Distribution Channel, the market is segmented as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Distribution channels. Based on Disease Indications, the market is segmented as Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Other disease Indication.
Based on Drug Class, the immunosuppressants segment is accounted as a significant contributor to the Immunology Drugs Market.
During the projection period, the immunosuppressants segment is anticipated to expand at a faster rate. Leading market participants' intense focus on R&D to establish the rising number of regulatory approvals for these pharmaceuticals is credited with this segment's quick expansion. Additionally, immunosuppressants are becoming more widely used in developing countries because of their superior therapeutic efficacy, which contributes to their rapid growth rate. The main driver of immunosuppressants is the rise in autoimmune diseases such as multiple sclerosis, alopecia areata, and arthritis. An increase in organ transplant procedures like kidney and liver transplants due to the rise in cases of organ failure fuels the development of immunosuppressants.
Based on Disease Indications, the inflammatory bowel disease segment is accounted as a major contributor to the Immunology Drugs Market.
In the forecast period, the market will be dominated by the segment for inflammatory bowel disease. Over the forecast period, market growth is anticipated to be fuelled by the increasing prevalence of Crohn's disease and ulcerative illness worldwide. The escalating rates of Crohn's disease and ulcerative colitis are caused by a number of factors, including immune system instability, environmental triggers, and genetic predisposition. Most people with Crohn's disease or ulcerative colitis have a family history of the condition. The market for treating inflammatory bowel illness is anticipated to develop as a result of this. Additionally, it is predicted that the market will rise in the next years due to the rising use of biologics for therapy and the availability of potent pipeline medications like upadacitinib, risankizumab, tofacitinib, ustekinumab, and others.
The North America Immunology Drugs Market holds a significant revenue share in the region.
Due to the availability of superior reimbursement laws, the huge potential to invest substantial funds in creating Immunology Drugs treatments, and the advancement of technology, North America dominates the worldwide market for Immunology Drugs pharmaceuticals. The larger patient pool in the regions, rising economies, increased government activities and increased awareness all point to the growing demand for Immunology Drugs drugs. The United States now dominates the global market due to its well-developed healthcare infrastructure, higher prevalence of chronic illnesses, and higher rates of diagnosis and treatment among patient populations.
The key players in the Immunology Drugs Market have shifted their focus toward bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and through partnerships with regional and international companies to expand their product offerings and expand their global market presence. Some of the major key players in the Immunology Drugs Market are Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp, and UCB S.